BioSpace News Archive

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today announced that its wholly-owned subsidiary, Quoin Pharmaceuticals, Inc., has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for QRX003.

Rehabtronics is pleased to announce that Genome BC is providing $1.25 million to support commercialization of Prelivia, the world’s first neuroscience-based technology designed to protect patients against deadly pressure injuries.

Allergan, an AbbVie company, announced that LASTACAFT® is now available without a prescription for the estimated 40% of Americans1 who live with ocular allergies.

NovaSignal Corp., a medical technology and data company specializing in the assessment and management of brain health, today announced that its NovaGuide™ Intelligent Ultrasound has been granted a Medical Device Licence by Health Canada.

CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, announced today that the company will release its 2021 fourth quarter and full year financial results after the market closes on Tuesday, March 29, 2022.

Cerner Corporation, a global healthcare technology company, announced that its Board of Directors declared a cash dividend to stockholders of $0.27 per issued and outstanding share.

NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) (“NeuroSense”), a company developing treatments for severe neurodegenerative diseases, announced today that the company’s CEO, Alon Ben-Noon, has been invited to present at the 2022 Virtual Growth Conference.

Ms. Chao has over 25 years of experience in the biotech and life sciences industries focused primarily on finance and corporate strategy.

The dose of NVG-291 in the first cohort is already above the highest corresponding dose that resulted in dramatic functional improvements in animal models.

Companies on the 2022 Inc. 5000 Regionals Southwest list had an average growth rate of 154 percent.